High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

Polushin, A. Yu.; Lopatina, Evgeniya; Zalyalov, Yury; Tsynchenko, Alexander; Totolyan, Natalia

doi:10.18620/ctt-1866-8836-2022-11-2-6-15

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, when using medium-intensity CR, the severity of HDIT complications according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) is mostly considered mild and moderate (Grade 0-3). Table 3 presents a list of potential late complications of HDIT-AHSCT when using the recommended protocols for MS [1,4,5,13,[19][20][21][30][31][32].…”

Section: Review Articlesmentioning

confidence: 99%

See 1 more Smart Citation

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction

Polushin¹,

Tsynchenko²,

Zalyalov³

et al. 2022

CTT

View full text Add to dashboard Cite

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) is a promising and effective method of treatment of autoimmune diseases, including multiple sclerosis. Over the past 20 years, the frequency and severity of side effects of therapy have been significantly reduced due to the accumulation of experience of transplant centers, changing principles of patient selection and decreased intensity of conditioning regimens. However, the medium-intensity therapeutic protocols may also be accompanied by complications. We have analyzed the literature data and our own experience on early and late side effects of HDIT-AHSCT. The profile of an appropriate schedule of HDIT-AHSCT is also presented, as determined by characteristics of the patients and the clinical course of multiple sclerosis. The types of HDIT-AHSCT are formulated, as based on the goals and expectations of the treatment approach.

show abstract

Section: Review Articlesmentioning

confidence: 99%

“…Analysis of research publications concerning the choice of optimal conditions and criteria for administering HDIT-AH-SCT in multiple sclerosis, as well as a description of the main stages of the method, was presented earlier [13].…”

Section: Introductionmentioning

confidence: 99%

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction

Polushin¹,

Tsynchenko²,

Zalyalov³

et al. 2022

CTT

View full text Add to dashboard Cite

show abstract

Autologous Stem Cell Transplantation for Autoimmune Diseases

Gil-Perotin,

Balaguer,

Chorão

et al. 2024

Comprehensive Hematology and Stem Cell Research

View full text Add to dashboard Cite

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in crohn disease: literature review

Ganich,

Shchukina,

Polushin

et al. 2024

jour

View full text Add to dashboard Cite

The literature review presents the current status of the method of high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in the treatment of Crohn’s disease.In recent decades, there has been an increase in Crohn’s disease. The frequency of CD the response rate to biopreparations ranges from 20 to 50%, up to 80% of patients need surgical treatment. Due to the insufficient effectiveness of therapy, an active research is underway for new therapeutic opportunities, one of which is the method of HDIT-AHSCT. In the Russian Federation, there are data on the use of mesenchymal stem cells for the treatment of CD, there are no studies on the use of HDIT-AHSCT in IBD. According to the EBMT register in the period from 1994 to 2023. more than 4000 HDIT-AHSCT were performed in patients with autoimmune diseases, the proportion of CD was 6.13% of all protocols. The HDIT-AHSCT procedure consists of the following stages: mobilization of autologous HSCs, apheresis and cryopreservation of HSCs, immunoablative conditioning and infusion of HSCs. Most of the publications on the use of HDIT-AHSCT in CD were not universal in the selection and management of patients. Currently, there is the only one completed RCT on the use of HDIT-AHSCT in CD, the results of which have not received a definite outcome. However, for a cohort of patients with refractory CD, it is necessary to consider the possibility of using this method. The review presents the indications and selection criteria for the HDIT-AHSCT protocol. Further studies of the HDIT-AHSCT in CD will help expand the therapeutic opportunities of treating patients with refractory CD to standard and biological therapy.

show abstract

High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

Cited by 3 publications

References 26 publications

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction

Autologous Stem Cell Transplantation for Autoimmune Diseases

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in crohn disease: literature review

Contact Info

Product

Resources

About